Glenmark Pharmaceuticals Ltd. on Thursday announced that it has slashed the price of its breast cancer drug Trastuzumab by 70%. The new price of the drug will be Rs. 15,749 per 440 mg vial, down from Rs. 54,000 earlier.
Trastuzumab is a monoclonal antibody that is used to treat HER2-positive breast cancer. It is a targeted therapy, which means that it works by targeting specific molecules on the surface of cancer cells. Trastuzumab is a very effective drug, but it is also very expensive.
Glenmark’s decision to slash the price of Trastuzumab is a welcome move. It will make the drug more affordable for patients and make it easier for them to access this life-saving treatment.
The price reduction is significant. The new price of Trastuzumab is now comparable to the price of other targeted therapies for HER2-positive breast cancer. This means that patients will no longer have to choose between Trastuzumab and other, less effective treatments, simply because of the price.
The price reduction is also likely to have a significant impact on the Indian market for Trastuzumab. Glenmark is the leading supplier of Trastuzumab in India, and its decision to slash the price is likely to force other manufacturers to reduce their prices as well. This will make the drug more affordable for even more patients.
The price reduction is a win-win for patients and for Glenmark. Patients will now have access to a life-saving treatment at a more affordable price, and Glenmark will be able to increase its market share.
The price reduction is also a sign of the growing competition in the Indian pharmaceutical market. As more and more companies enter the market, they are under pressure to reduce their prices in order to compete. This is good news for patients, as it means that they will have access to more affordable and effective treatments.
Impact of the price reduction
The price reduction of Trastuzumab is likely to have a significant impact on the Indian market for the drug. It is expected to make the drug more affordable for patients and increase the demand for it. This could lead to increased competition among manufacturers, which could further drive down prices.
The price reduction is also likely to have a positive impact on the availability of Trastuzumab. As the demand for the drug increases, manufacturers are likely to increase production. This will make the drug more accessible to patients and ensure that they have access to the treatment they need.
Overall, the price reduction of Trastuzumab is a positive development. It is good news for patients, as it will make the drug more affordable and accessible. It is also good news for the Indian pharmaceutical market, as it will increase competition and drive down prices.
